Simplify Asset Management Inc. Has $2.35 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Simplify Asset Management Inc. boosted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 62.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 122,185 shares of the company’s stock after acquiring an additional 46,992 shares during the period. Simplify Asset Management Inc.’s holdings in Syndax Pharmaceuticals were worth $2,352,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in SNDX. Atria Investments Inc acquired a new stake in Syndax Pharmaceuticals during the third quarter worth approximately $364,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Syndax Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,367 shares of the company’s stock worth $315,000 after purchasing an additional 6,383 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Values First Advisors Inc. bought a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at $30,000. Finally, Assenagon Asset Management S.A. grew its holdings in Syndax Pharmaceuticals by 8.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 466,028 shares of the company’s stock valued at $8,971,000 after buying an additional 37,079 shares in the last quarter.

Analyst Ratings Changes

SNDX has been the subject of a number of research reports. The Goldman Sachs Group lifted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Bank of America lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. HC Wainwright increased their target price on shares of Syndax Pharmaceuticals from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup lifted their price target on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Syndax Pharmaceuticals Trading Down 2.4 %

Shares of SNDX stock traded down $0.40 during trading hours on Friday, reaching $16.39. The company’s stock had a trading volume of 296,369 shares, compared to its average volume of 1,107,029. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $25.34. The firm’s 50 day simple moving average is $18.99 and its 200-day simple moving average is $20.27.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the business earned ($0.73) earnings per share. Equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.61 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).